By Katherine Hamilton
Simulations Plus posted a lower profit for its first fiscal quarter of 2025 as the cost of its software and services rose.
The company, which provides modeling and simulation software to biopharmaceutical companies, posted a profit of $206,000, or 1 cent a share, in the three months ended Nov. 30, compared with $2 million, or 10 cents a share, a year earlier.
Stripping out certain one-time items, adjusted per-share earnings were 17 cents, in line with what FactSet analysts expected.
Revenue rose 31% to $18.9 million. Analysts surveyed by FactSet forecast revenue of $18.8 million.
Simulations Plus reiterated its 2025 guidance of $90 million to $93 million in revenue.
Costs of revenues for software and services roughly doubled year-over-year. Services revenue increased 19%, but faced some challenges because client-driven data was postponed, the company said.
"Overall, our team achieved solid results despite ongoing funding challenges and cost constraints in the pharma and biotech sectors," said chief executive Shawn O'Connor.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
January 07, 2025 16:36 ET (21:36 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.